Rostafuroxin: An ouabain-inhibitor counteracting specific forms of hypertension

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1802, Issue 12, 2010, Pages 1254-1258

  Ferrari, Patrizia ^a  

^a Prassis Sigma Tau Research Institute   (Italy)

Author keywords

Adducin; Endogenous ouabain; Essential hypertension; Genetics; Therapy

Indexed keywords

17BETA (3 FURYL) 5BETA ANDROSTANE 3BETA,14BETA,17ALPHA TRIOL; ADDUCIN; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); OUABAIN; PLACEBO;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DNA POLYMORPHISM; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; HYPERTROPHY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE;

ANDROSTANOLS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALMODULIN-BINDING PROTEINS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION; KIDNEY; MUTATION; OUABAIN; POLYMORPHISM, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SODIUM; SODIUM-POTASSIUM-EXCHANGING ATPASE; SRC-FAMILY KINASES;

ANIMALIA; STROPHANTHUS GRATUS;

EID: 78049232372     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.01.009     Document Type: Review

References (51)

1. Kearney P.M., Whelton M., Reynolds K., Muntner P., Whelton P.K., He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005, 365:217-223.
2. Horan M.J., Mockrin S.C. Heterogeneity of hypertension. Am. J. Hypertens. 1992, 5:110S-113S.
3. Materson B.J. Variability in response to antihypertensive therapy. Am. J. Med. 2007, 120:S10-S20.
4. Chobanian A.V. Does it matter how hypertension is controlled?. N. Engl. J. Med. 2008, 359:2485-2488.
5. Krousel-Wood M., Hyre A., Muntenr P., Morisky D. Methods to improve medication adherence in patients with hypertension: current status and future directions. Curr. Opin. Cardiol. 2005, 20(4):296-300.
6. Ong K.L., Cheung B.M., Man Y.B., Lau C.P., Lam K.S. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007, 49(1):69-75.
7. Cookson W., Liang L., Abecasis G., Moffatt M., Lathrop M. Mapping complex disease traits with global gene expression. Nat. Rev. Genet. 2009, 10:184-194.
8. Hopkins A.L. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4:682-690.
9. Roses A.D. Pharmacogenetics in drug discovery and development: a translational perspective. Nat. Rev. Drug Discov. 2008, 7:807-817.
10. Roman R.J. Abnormal renal hemodynamics and pressure-natriuresis relationship in Dahl salt-sensitive rats. Am. J. Physiol. Renal. Fluid Electrolyte Physiol. 1986, 251:F57-F65.
11. Manunta P., Maillard M., Tantardini C., Simonini M., Lanzani C., Citterio L., Stella P., Casamassima N., Burnier M., Hamlyn J.M., Bianchi G. Relationships among endogenous ouabain, alpha-adducin polymorphisms and renal sodium handling in primary hypertension. J. Hypertens. 2008, 26:914-920.
12. Bianchi G. Genetic variations of tubular sodium reabsorption leading to 'primary' hypertension: from gene polymorphism to clinical symptoms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289:R1536-R1549.
13. Blaustein M.P., Zhang J., Chen L., Hamilton B.P. How does salt retention raise blood pressure?. Am. J. Physiol. Regul. Integr. Comp. Physiol 2006, 290:R514-R523.
14. Ferrari P., Bianchi G. Lessons from experimental genetic hypertension. Hypertension: Pathophysiology, Diagnosis and Management 1995, 126. Raven Press Ltd, NY, chapt. 74. J.H. Laragh, B.M. Brenner (Eds.).
15. Toka H.R., Luft F.C. Monogenic forms of human hypertension. Semin. Nephrol. 2002, 22(2):81-88.
16. +-ATPase emerges as an interesting drug target. J. Int. Med. 2006, 261:44-52.
17. Ferrandi M., Minotti E., Salardi S., Florio M., Bianchi G., Ferrari P. Ouabain-like factor in Milan hypertensive rats. Am. J. Physiol. 1992, 263:F739-F748.
18. Ferrandi M., Manunta P., Balzan S., Hamlyn J.M., Bianchi G., Ferrari P. Ouabain-like factor quantification in human tissues and plasma: comparison of two independent assays. Hypertens 1997, 30:886-896.
19. Manunta P., Messaggio E., Ballabeni C., et al. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 2001, 38(2):198-203.
20. Bianchi G., Tripodi G., Casari G., et al. Two point mutations within the adducin genes are involved in blood pressure variation. Proc. Natl. Acad. Sci. 1994, 91:3999.
21. Casari G., Barlassina C., Cusi D., et al. Association of the alpha-adducin locus with essential hypertension. Hypertension 1995, 25:320.
22. Cusi D., Barlassina C., Azzani T., et al. Polymorphism of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997, 349:1353.
23. Bianchi G. Genetic variations of tubular sodium reabsorption leading to "primary" hypertension: from gene polymorphism to clinical symptoms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2005, 289:R1536-R1549.
24. Ferrandi M., Molinari I., Barassi P., Minotti E., Bianchi G., Ferrari P. Organ hypertrophic signaling within caveolae membrane subdomains triggered by ouabain and antagonized by PST2238. J. Biol. Chem. 2004, 279(32):33306-33314.
25. Manunta P., Stella P., Rivera R., et al. Left ventricular mass, stroke volume and ouabain-like factor in essential hypertension. Hypertension 1999, 34(3):450-456.
26. Pierdomenico S.D., Bucci A., Manunta P., et al. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension. Am. J. Hypertens. 2001, 14(1):44-50.
27. Pitzalis M.V., Hamlyn J.M., Messaggio E., et al. Independent and incremental prognostic value of endogenous ouabain in idiopathic dilated cardiomyopathy. Eur. J. Heart Failure 2006, 8:179-186.
28. Bianchi G. Genetic variation of alpha-adducin results in "primary" hypertension. In: Molecular Basis of Diseases, special issue on Hypertension. BBA; chapter # 19.
29. Manunta P. Endogenous ouabain in cardiovascular function and disease. In: Molecular Basis of Diseases, special issue on Hypertension. BBA; chapter # 18.
30. +-ATPase forms a functional signaling complex. Mol. Biol. Cell 2006, 17:317-326.
31. +-ATPase reveals that the enzyme can act as a pump and a signal transducer. Cell. Mol. Biol. 2001, 47:383-390.
32. +-ATPase. J. Biol. Chem. 2004, 279:17250-17259. 17250-17259.
33. Zhang J., Lee M.Y., Cavalli M., et al. Sodium pump alpha2 subunits control myogenic tone and blood pressure in mice. J. Physiol. 2005, 569:243-256.
34. Matsuoka Y., Li X., Bennett V. Adducin: structure, function and regulation. Cell. Mol. Life Sci. 2000, 57(6):884-895.
35. + reabsorption. Am. J. Physiol. Renal. Physiol. 2008, 295(2):F478-F487.
36. Efendiev R., Krmar R.T., Ogimoto G., Zwiller J., Tripodi G., Katz A.I., et al. Hypertension-linked mutation in the adducin alpha-subunit leads to higher AP2-mu2 phosphorylation and impaired Na+, K+-ATPase trafficking in response to GPCR signals and intracellular sodium. Circ. Res. 2004, 95:1100-1108.
37. Ferrandi M., Salardi S., Tripodi M.G., Barassi P., Rivera R., Manunta P., Goldshleger R., Ferrari P., Bianchi G., Karlish S. Evidence for an interaction between adducin and Na, K'ATPase: relation to genetic hypertension. Am. J. Physiol. 1999, 277(46):1338-1349.
38. +ATPase alterations in ouabain and adducin-dependent hypertension. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 290(3):R529-R535.
39. Ferrari P., Torielli L., Ferrandi M., et al. PST 2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain. J. Pharm. Exp. Ther. 1998, 285(1):83-94.
40. +ATPase in genetic hypertension. J. Pharm. Exp. Ther. 1999, 288(3):1074-1083.
41. Ferrari P., Ferrandi M., Valentini G., Manunta P., Bianchi G. Targeting ouabain and adducin-dependent mechanisms of hypertension and cardiovascular remodelling as a novel pharmacological approach. Med. Hypotheses 2007, 68:1307-1314.
42. +ATPase and antagonizes the pressor effect of OLF. Cardiovasc. Drug Rev. 1999, 17(1):39-57.
43. Ferrandi M., Barassi P., Minotti E., et al. PST 2238: a new antihypertesive compound that modulates renal Na-K pump function without diuretic activity in Milan hypertensive rats. J. Cardiovasc. Pharmacol. 2002, 40(6):881-889.
44. Staessen J.A., Kuznetsova T., Acceto R., et al. OASIS-HT: design of a pharmacogenomic dose-finding study. Pharmacogenomics 2005, 6:755-775.
45. +ATPase. J. Biol. Chem. 2000, 275(36):27832-27837.
46. Oparil S., Yarows S.A., Patel S., Fang H., Zhang J., Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet 2007, 370:221-229.
47. Suonsyrja T., Hannila-Handelberg T., Fodstad H., Donner K., Kontula K. Renin-angiotensin system and α-adducin gene polymorphism and their relation to responses to antihypertensive drugs: results from a GENRES study. Am. J. Hypertens. 2009, 22:169-175.
48. Elmfeldt D., Olofsson B., Meredith P. The relationship between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Pressure 2002, 11:293-301.
49. Wilson T.W., Lacourciere Y., Barnes C. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. Can. Med. Ass. J. 1998, 159:469-476. for the Canadian Cozaar Hyzaar Amlodipine Trial Study Group, for the Canadian Cozaar Hyzaar Amlodipine Trial Study Groupfor the Canadian Cozaar Hyzaar Amlodipine Trial Study Group.
50. Baguet J.P., Nisse-Durgeat S., Mouret S., Asmar R., Mallion J.M. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8mg, and losartan, 50mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring. J. Clin. Pract. 2006, 60:391-398.
51. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomize trials. Lancet 2003, 362:1527-1535. Blood Pressure Lowering Treatment Trialist' Collaboration.